Supplementary Figure – Generalizability of ORIENT-11 Trial Results to a US Standard of Care Cohort with Advanced Non-Small Cell Lung Cancer
Supplementary Figure 1. Patient attrition.
Abbreviations: 1L, first line therapy; ALK, anaplastic lymphoma kinase; CNS, central nervous system; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitors; aNSCLC, advanced non-small cell lung cancer
a Index date = start date of first line therapy pembrolizumab + pemetrexed + platinum
b Positive result at any time